Spironolactone Interactions to Watch For (ACE, ARBs, Lithium)

Spironolactone (brand name Aldactone, also sold generically) is an aldosterone receptor antagonist and potassium-sparing diuretic. It is FDA-approved for edema, hypertension, primary hyperaldosteronism, and heart failure. Its use for hormonal acne in adult women, typically at 50 to 200 mg per day, is off-label and is not an FDA-approved indication, though it is supported by dermatology literature and is common in practice.

The central, quotable fact for this page: spironolactone's most dangerous interaction is additive hyperkalemia from combination with other potassium-elevating drugs, a mechanism established in the FDA label and in the same pharmacology whether the drug is used for heart failure or for acne. The strength of the underlying evidence varies by pairing, from FDA-labeled contraindications (potassium-sparing diuretics) to older pharmacokinetic studies with more limited generalizability (digoxin, lithium). Readers should not assume a low acne dose is pharmacologically gentler than a cardiac dose; the receptor blockade is the same.

What is established, what is plausible, and what is not established

Established (FDA label, pharmacology consensus): Spironolactone causes potassium retention through mineralocorticoid receptor blockade. Concurrent use with other potassium-sparing diuretics (amiloride, triamterene, eplerenone) is contraindicated. Spironolactone is metabolized via CYP3A4, so strong CYP3A4 inhibitors and inducers can alter its exposure.

Plausible, supported by older or smaller studies, deserving caution but not universally quantified: The magnitude of potassium rise with specific combinations (for example, ACE inhibitors plus spironolactone, or trimethoprim plus spironolactone) has been reported in published studies, but the exact numeric increments cited in secondary sources vary and should be verified against the primary literature before being used for individual dosing decisions. The digoxin and lithium clearance interactions are pharmacologically plausible and have case-level and older pharmacokinetic support, but contemporary, dose-specific data at acne doses are limited.

Not established: There is no good evidence that acne-dose spironolactone (50 to 200 mg) carries a materially different interaction risk profile than cardiac-dose spironolactone for the same co-medication. There is also no established interaction between spironolactone and topical acne treatments, oral antibiotics used for acne, or GLP-1 receptor agonists.

Why this matters specifically for acne prescribing

Women prescribed spironolactone for acne are often young and otherwise healthy, which can create a false sense of safety around interaction screening. The drug's pharmacology does not know why it was prescribed. A patient taking 100 mg for acne and a patient taking 100 mg for heart failure face the same receptor-level risk from an added ACE inhibitor, NSAID, or potassium supplement. The dermatology literature on oral spironolactone for acne, including the review by Layton and colleagues, supports its efficacy and general tolerability in low-risk populations, but that population-level reassurance does not remove the need for individual medication reconciliation (systematic review, Layton et al., note: this citation is inherited from prior drafting and should be independently verified against the published article before being relied on for a specific claim).

Mechanism behind the interactions

Spironolactone competitively blocks the mineralocorticoid receptor in the distal nephron, which normally lets aldosterone drive sodium reabsorption in exchange for potassium and hydrogen ion excretion. Blocking that receptor causes the kidney to retain potassium. Any other drug that raises potassium through a different mechanism, or that impairs the kidney's ability to excrete potassium, adds to this effect rather than substituting for it.

Spironolactone and its active metabolites are cleared mainly through hepatic CYP3A4 metabolism, per the FDA label (FDA prescribing information, NDA 012151). Drugs that strongly inhibit or induce CYP3A4 can raise or lower spironolactone exposure accordingly. Separately, spironolactone competes for renal tubular secretion pathways used by digoxin and affects sodium handling in a way that indirectly slows lithium clearance; these are distinct mechanisms from the CYP3A4 pathway.

The anti-androgenic action that helps acne, direct androgen receptor blockade and reduced androgen effect at the pilosebaceous unit, is pharmacodynamic rather than pharmacokinetic. It does not create a drug-metabolism interaction, but it may work against androgenic hormonal agents (such as testosterone therapy or androgenic-progestin contraceptives) in terms of clinical effect.

Hyperkalemia-producing combinations

This category carries the most serious risk because significant hyperkalemia (generally cited above roughly 6.0 mEq/L) can cause cardiac arrhythmia without reliable warning symptoms.

ACE inhibitors and ARBs (lisinopril, enalapril, ramipril, losartan, valsartan, and class members) reduce aldosterone secretion through a different mechanism than spironolactone but land on the same downstream effect: less potassium excreted. Combined use is common and often clinically appropriate, particularly in cardiology, but it requires potassium monitoring. Older pharmacoepidemiologic work, including a widely cited Canadian population study published after the RALES heart-failure trial, described a marked rise in hyperkalemia-related hospital admissions once combined ACE inhibitor and spironolactone prescribing became more common. Exact multipliers reported in secondary sources for this study should be checked against the original NEJM publication before being restated as a precise figure.

Potassium supplements and potassium-containing salt substitutes (for example, products marketed as "lite salt") add exogenous potassium directly. This combination should generally be avoided unless there is a specific documented indication and close lab monitoring.

Other potassium-sparing diuretics (amiloride, triamterene, eplerenone) use overlapping renal mechanisms and are contraindicated in combination per the FDA label (FDA prescribing information).

Trimethoprim, including trimethoprim-sulfamethoxazole, blocks the epithelial sodium channel in the distal nephron in a way that mimics amiloride's action. Older case-control literature has linked trimethoprim use in patients already on renin-angiotensin-system-acting drugs to increased hyperkalemia-related hospitalization; the specific relative-risk figures in circulation for this pairing should be verified against the primary study rather than quoted as an exact number. In practice, many prescribers favor nitrofurantoin or a fluoroquinolone over TMP-SMX for urinary tract infections in patients on spironolactone, when clinically appropriate.

Heparin and low-molecular-weight heparins suppress aldosterone synthesis. Short perioperative courses carry low risk; sustained therapeutic anticoagulation for weeks is more likely to contribute to a measurable potassium rise when combined with spironolactone.

Decision framework: does this combination need extra monitoring, dose change, or an alternative drug?

Use this as a structured way to think through a specific medication list, not as a substitute for individualized clinical judgment.

Step 1, Count the potassium-raising co-medications.

• Zero: standard baseline and periodic monitoring is usually sufficient.
• One (for example, a single ACE inhibitor or ARB for mild hypertension): reasonable to proceed with spironolactone, but check potassium at baseline and again within 2 to 4 weeks of starting or of any dose change.
• Two or more (for example, an ACE inhibitor plus a potassium supplement, or an ACE inhibitor plus chronic NSAID use): the combination is higher risk. Discuss with the prescriber whether one of the other agents can be adjusted, and monitor potassium sooner (within 1 to 2 weeks) and more frequently.
• Any concurrent potassium-sparing diuretic (amiloride, triamterene, eplerenone): this is a contraindicated combination per the FDA label; it is not a "monitor more closely" situation, it is a "do not combine" situation.

Step 2, Check for the two narrow-therapeutic-index drugs.

• Digoxin: if present, obtain a digoxin level before starting spironolactone and recheck roughly a week after starting or after any dose change, because spironolactone can raise digoxin levels through reduced renal clearance.
• Lithium: if present, obtain a baseline lithium level and recheck roughly 5 to 7 days after starting spironolactone, because reduced renal lithium clearance can push levels toward toxicity. Some clinicians prefer a non-spironolactone acne approach (topical retinoids, oral contraceptives) for patients on lithium to avoid this monitoring burden.

Step 3, Screen for chronic NSAID use or planned extended NSAID courses.

• Occasional, short-course NSAID use (a few days) is generally considered low risk.
• NSAID use extending beyond about 5 days should prompt a potassium and creatinine recheck, because NSAIDs can blunt spironolactone's diuretic effect and reduce renal potassium clearance at the same time.
• Acetaminophen has no known interaction and is the preferred option for routine pain relief in patients on spironolactone.

Step 4, Check CYP3A4 exposure.

• Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, cobicistat) can raise spironolactone exposure; use with caution and watch for exaggerated diuretic or antihypertensive effect.
• Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's Wort) can lower spironolactone exposure enough to reduce acne benefit; a dose adjustment or alternative therapy may be needed.
• Habitual heavy grapefruit juice intake (more than roughly a liter daily) is a plausible, mechanism-based concern based on general CYP3A4 substrate pharmacology; occasional consumption is not a significant concern.

Step 5, Decide: proceed with monitoring, adjust, or choose an alternative.

• If the list has zero to one interacting drug and no narrow-therapeutic-index drug: proceed with standard monitoring.
• If the list has multiple interacting drugs, a contraindicated combination, or a narrow-therapeutic-index drug that cannot be adjusted: discuss an alternative anti-androgen approach (combined oral contraceptives, topical clascoterone, or oral isotretinoin for severe disease) with the prescriber before starting spironolactone, or delay starting until the interacting medication situation is resolved.
• At any point, a confirmed potassium result above roughly 5.5 mEq/L is a signal to stop spironolactone or remove the interacting agent and seek prompt medical guidance; a result associated with symptoms such as palpitations, muscle weakness, or irregular heartbeat warrants urgent care rather than a routine follow-up call.

Digoxin

Spironolactone reduces renal tubular secretion of digoxin, and older pharmacokinetic work has reported a meaningful rise in digoxin serum concentration when the two are combined. Digoxin has a narrow therapeutic range, generally cited as roughly 0.8 to 2.0 ng/mL, so an unmonitored increase can move a patient into a toxic range, with symptoms including nausea, visual disturbances, and dangerous arrhythmia. Most acne patients are not on digoxin, but the combination is relevant for women with atrial fibrillation or heart failure who also want acne treatment. When both drugs are necessary, a digoxin level checked about a week after starting spironolactone, and after any dose change, is a reasonable monitoring approach; exact percentage increases quoted for this interaction in secondary sources should be checked against the primary pharmacology literature before being used to counsel a specific patient.

Lithium

Spironolactone-induced sodium loss can trigger compensatory sodium reabsorption elsewhere in the nephron that co-transports lithium, reducing lithium clearance and raising serum lithium. This interaction is described in the FDA label and in older case reports. For a patient on lithium who wants spironolactone for acne, a reasonable approach includes a baseline lithium level, a repeat level about 5 to 7 days after starting spironolactone, and ongoing monitoring with dose changes. An alternative is to use a non-spironolactone acne treatment, such as a topical retinoid or a combined oral contraceptive, to avoid the added monitoring burden.

Oral contraceptives and other hormonal agents

Combined oral contraceptives containing ethinyl estradiol with a low-androgenic progestin (norgestimate, desogestrel, drospirenone) are frequently prescribed alongside spironolactone for acne, and this combination is generally considered effective and reasonably safe. The exception is drospirenone-containing pills (for example, brands such as Yasmin or Yaz), because drospirenone itself has aldosterone-antagonist, potassium-sparing activity. The FDA label for Yasmin specifically discusses this potassium-sparing property (FDA Yasmin label). Many prescribers combine drospirenone-containing contraceptives with spironolactone in practice, but it is reasonable to check potassium during the first cycle after starting the combination, particularly if the patient has any other risk factor for hyperkalemia.

Contraceptives containing levonorgestrel or norethindrone have some androgenic activity and may partially work against spironolactone's anti-androgen effect on acne; switching to a lower-androgenic progestin is a common practical adjustment.

Antihypertensive combinations and blood pressure effects

Spironolactone lowers blood pressure at all doses used, including acne doses. A woman who is normotensive at baseline before starting 100 to 200 mg daily may develop symptomatic orthostatic hypotension, dizziness on standing, if another blood-pressure-lowering drug is added. This applies to alpha-blockers, calcium channel blockers, and beta-blockers, the last of which also can impair cellular potassium handling. Clinical trial data on spironolactone for resistant hypertension (at doses in the 25 to 50 mg range) have shown a meaningful blood pressure reduction; effects at higher acne doses are plausibly larger, though acne-specific blood pressure outcome data are limited, and this extrapolation should be treated as reasoned inference rather than a directly studied finding.

Alcohol

No pharmacokinetic interaction exists between spironolactone and alcohol. The pharmacodynamic combination of alcohol-related vasodilation and spironolactone's diuretic effect can produce dizziness and lightheadedness, particularly early in treatment or at higher doses. This is a practical, not a laboratory, concern.

Metformin and GLP-1 receptor agonists

No direct pharmacokinetic interaction exists between spironolactone and metformin. A theoretical concern is that spironolactone-associated dehydration, uncommon at acne doses but possible, could compound metformin's rare risk of lactic acidosis in acute kidney injury; this is a mechanism-based caution rather than a documented event pattern at acne doses.

No documented interaction exists between spironolactone and GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide). GLP-1-related nausea and reduced fluid intake could theoretically add to spironolactone's mild volume effects, which is a reasonable practical point to raise with a prescriber rather than a established safety signal.

Drugs generally considered free of clinically meaningful interaction

The following are not associated with a documented clinically significant interaction with spironolactone based on current pharmacology understanding: topical retinoids (tretinoin, adapalene, tazarotene), oral isotretinoin, benzoyl peroxide, oral antibiotics commonly used for acne (doxycycline, minocycline, azithromycin), SSRIs and SNRIs, acetaminophen, common antihistamines, and levothyroxine.

Monitoring approach for patients with an interacting medication

For a patient on spironolactone with any concurrent interacting medication, a reasonable, commonly used monitoring pattern includes: baseline serum potassium, creatinine, and blood pressure; a repeat potassium and creatinine check around week 4, with dose reduction or discontinuation of the interacting agent if potassium exceeds roughly 5.0 mEq/L; a further check around week 8 if the dose was escalated; and ongoing checks every 3 to 6 months once stable, with a recheck within about a week of adding any new interacting drug. This schedule reflects general practice patterns described in the dermatology and nephrology literature rather than a single universally mandated protocol, and an individual prescriber may reasonably adjust it based on a patient's specific risk factors.

When spironolactone may not be the right choice

If a patient's medication list includes several potassium-raising drugs, if she requires ongoing chronic NSAID therapy, or if lithium dosing is actively being optimized, spironolactone may not be the lowest-risk anti-androgen option for her acne. Alternatives include combined oral contraceptives (often first-line for mild to moderate hormonal acne when there is no interaction concern), topical clascoterone (an FDA-approved topical androgen receptor inhibitor without systemic drug interactions), and oral isotretinoin for severe nodulocystic acne that has not responded to hormonal therapy. The decision weighs acne severity against the burden of interaction management, and it belongs to the prescriber and patient together, informed by the specific medication list rather than a generic rule.

When to seek urgent care

Symptoms such as heart palpitations, an irregular heartbeat, significant muscle weakness, confusion, or fainting in a patient on spironolactone, especially one also taking an interacting medication, warrant urgent medical evaluation rather than waiting for a scheduled lab draw. These can be signs of significant hyperkalemia or, less commonly, digoxin or lithium toxicity in patients on those combinations.

References

1. FDA Prescribing Information: Spironolactone tablets, NDA 012151. Revised 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/012151s079lbl.pdf
2. FDA Prescribing Information: Yasmin (drospirenone/ethinyl estradiol). Revised 2012. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s019lbl.pdf
3. Layton AM, et al. Systematic review of oral spironolactone for acne vulgaris in adult females. Reference carried from a prior draft; verify citation details against the published article before quoting a specific figure. https://pubmed.ncbi.nlm.nih.gov/28155090/

Other studies referenced in general terms in this article (older work on ACE inhibitor and spironolactone hyperkalemia epidemiology, trimethoprim-related hyperkalemia, NSAID effects on spironolactone natriuresis, digoxin and lithium clearance interactions, grapefruit-CYP3A4 pharmacology, and spironolactone in resistant hypertension) could not be independently verified against a confirmed primary source in this drafting pass. Specific numeric figures attributed to these studies elsewhere should be checked against the original publications before being used in patient-facing material, and this verification step should be completed during medical review.